Palvella Therapeutics, Inc. (NASDAQ: PVLA) is a Healthcare company (Biotechnology) with a market capitalization of $2.1B. The Maz Rating grades it against the other companies in its sector.
Palvella Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $144.35, Palvella Therapeutics, Inc. trades at 10.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -44.4%, return on invested capital of -31.3% and a free cash flow yield of -2.0%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 16.01. Over the past 52 weeks the share price ranged from $72.22 to $179.95, with a beta of -0.17.
Palvella Therapeutics, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 1 Strong Buy and 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Palvella Therapeutics, Inc. (PVLA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.3% / 30% · Interest income / Revenue 255100000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.3% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 255100000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.3% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 255100000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.10% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 98.9% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 255100000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 98.9% / 33.33% · (Cash+Recv) / Total Assets 98.9% / 33.33% · Interest income / Revenue 255100000.0% / 5% | Fail |
No. As of September 2026, Palvella Therapeutics, Inc. (PVLA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Palvella Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 255100000.0% of each dividend: Palvella Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.